Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab in chronic antibody-mediated rejection post-kidney transplant
NCT03380377Phase 2Completed
- Start
- Feb 2018
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clazakizumab in antibody mediated rejection (AMR). Started Feb 2018; status: completed.
02
Drugs
clazakizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03380377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03380377.